We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.66B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
+$327M
(+24%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.5%
Top 10 Holdings %
Top 10 Hldgs %
40.47%
Holding
329
New
71
Increased
98
Reduced
59
Closed
29
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 90.27% |
| 2 | Financials | 1.54% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Arbutus Biopharma
ABUS
$901M
| $14.1M | 0.85% |
3,133,175
-2,281,934
| -42% | -$9.98M |
|
27
Amylyx Pharmaceuticals
AMLX
$1.98B
| $13.9M | 0.84% |
1,000,604
+110,248
| +12% | +$1.55M |
|
28
Celldex Therapeutics
CLDX
$3.01B
| $13.6M | 0.82% |
427,816
-218,951
| -34% | -$5.97M |
|
29
Taysha Gene Therapies
TSHA
$1.78B
| $13.3M | 0.8% |
2,979,429
+483,620
| +19% | +$2.25M |
|
30
Xenon Pharmaceuticals
XENE
$6.55B
| $13.3M | 0.8% |
228,899
+24,930
| +12% | +$1.15M |
|
31
Sutro Biopharma
STRO
$431M
| $13.1M | 0.79% |
524,441
+457,364
| +682% | +$8.27M |
|
32
Revolution Medicines
RVMD
$39.2B
| $13M | 0.78% |
133,893
-11,186
| -8% | -$1.13M |
|
33
Enliven Therapeutics
ELVN
$3.8B
| $12.9M | 0.78% |
329,540
+299,540
| +998% | +$8.3M |
|
34
CG Oncology
CGON
$6.44B
| $12.6M | 0.76% |
185,699
-72,440
| -28% | -$4.1M |
|
35
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
| $12.4M | 0.75% |
135,585
| – | – |
|
36
Establishment Labs
ESTA
$2.67B
| $12.1M | 0.73% |
213,473
+42,051
| +25% | +$2.87M |
|
37
Replimune Group
REPL
$813M
| $12.1M | 0.73% |
1,582,987
+341,665
| +28% | +$2.61M |
|
|
IVA
38
Inventiva
IVA
$1.06B
| $12.1M | 0.73% |
2,174,398
-535,448
| -20% | -$3.26M |
|
39
Ionis Pharmaceuticals
IONS
$9.04B
| $12M | 0.72% |
160,338
+13,208
| +9% | +$1.04M |
|
40
Nektar Therapeutics
NKTR
$2.31B
| $11.6M | 0.7% |
161,252
+89,221
| +124% | +$5.08M |
|
41
Inhibikase Therapeutics
IKT
$323M
| $11.1M | 0.67% |
6,606,572
-1,457,377
| -18% | -$2.59M |
|
42
ARS Pharmaceuticals
SPRY
$750M
| $10.9M | 0.66% |
1,361,536
+991,967
| +268% | +$9.51M |
|
|
TERN
43
CALL
DELISTED
Terns Pharmaceuticals
TERN
| $10.5M | 0.63% |
+200,000
| New | +$8.21M |
|
|
HLXC
44
Helix Acquisition Corp III
HLXC
$231M
| $10.3M | 0.62% |
+1,000,000
| New | +$10.2M |
|
45
Ovid Therapeutics
OVID
$465M
| $10.1M | 0.61% |
4,544,113
+259,113
| +6% | +$463K |
|
|
OKUR
46
OnKure Therapeutics
OKUR
$170M
| $10.1M | 0.61% |
2,434,941
+1,420,783
| +140% | +$4.39M |
|
47
Regeneron Pharmaceuticals
REGN
$69.7B
| $9.39M | 0.56% |
12,154
+103
| +0.9% | +$78.9K |
|
48
MoonLake Immunotherapeutics
MLTX
$1.67B
| $8.52M | 0.51% |
+457,137
| New | +$7.57M |
|
49
Lexeo Therapeutics
LXEO
$372M
| $8.42M | 0.51% |
1,467,350
+74,189
| +5% | +$526K |
|
|
IRD
50
Opus Genetics
IRD
$287M
| $8.41M | 0.51% |
1,849,004
+1,809,004
| +4,523% | +$6.26M |
|
Similar funds
GWM
GACM
RIA
CPO
NRI
JPM
GC
FA